Explore the words cloud of the Kinaddict project. It provides you a very rough idea of what is the project "Kinaddict" about.
The following table provides information about the project.
UNIVERSITE LIBRE DE BRUXELLES
|Coordinator Country||Belgium [BE]|
|Total cost||178˙320 €|
|EC max contribution||178˙320 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2019-09-16 to 2021-09-15|
Take a look of project's partnership.
|1||UNIVERSITE LIBRE DE BRUXELLES||BE (BRUXELLES)||coordinator||178˙320.00|
In decades, the 5-year survival rate of several cancers has barely been improved and the esophageal squamous cell carcinoma (eSCC) is not different with a rate around 25%. In order to increase the survival, chemoradiotherapy prior surgery has become the reference for eSCC despite still a high mortality. eSCC tumors harbor a variety of genetic alterations directly or indirectly affecting the activity of kinases involved in signaling pathways, the cell cycle or the proliferation. Evidence on how eSCC tumors are addicted to such oncogenic alterations remains missing to evaluate alternative treatment modalities. The heterogeneity of eSCC tumors presenting deregulations of diverse constellations of kinases has rendered difficult the development of a unique therapeutic strategy similar to prior successes targeting EGFR or BCR-ABL. However, as the CDK4 activity lies downstream from most of the oncogenic deregulations of signalling pathways, it has been proposed to represent the therapeutic target of choice, confirmed by the first approval by the FDA/EMA of 3 CDK4/6 inhibitors to treat ER breast cancer. Despite this, not all tumors respond to CDK4 inhibition and long-term treatment triggers escape mechanisms. In this context, the main aim of the present proposal consists to preclinically evaluate if and how eSCC respond to inhibitors targeting kinases with an altered activity using a multi-omics approach. In this cancer, we will (1) identify the kinases with a deregulated activity associated to different genetic landscapes and determine the addiction of eSCC to their activity, (2) characterize the sensitivity of eSCC tumors to CDK4 inhibition and decipher their molecular response for effective combined targeted therapy, and (3) experimentally define the treatment modalities of eSCC in mouse models. The results will provide a strong basis to extend the study with clinicians to human tumors to determine biomarkers of responsiveness to efficient alternative therapy.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KINADDICT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "KINADDICT" are provided by the European Opendata Portal: CORDIS opendata.
Natural Product-Inspired Therapies for Leishmaniasis and Chagas DiseaseRead More
Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and IconographyRead More
A multilinear approach to the restriction problem with applications to geometric measure theory, the Schrödinger equation and inverse problemsRead More